AQVESME is the only FDA-approved medicine for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemiaMarketed under AQVESME brand name in the U.S. for thalassemia ...

Altimmune's pemvidutide shows strong Phase IIb results for MASH, promising Phase III prospects. Read here for more analysis on ALT stock.

The KINECT-DCP trial evaluated the efficacy and safety of valbenazine in patients with dyskinesia due to cerebral palsy who experience choreiform movements.

Analysts said the outcome is disappointing because there are no approved treatments for dyskinetic cerebral palsy, but the setback had little impact on Neurocrine's valuation.

Authorization expands Keeper's ability to safeguard high-impact federal systems with industry-leading privileged access managementCHICAGO, Dec. 23, 2025 ...

Hope is preparing for close-out meetings with the FDA. Chang said the team is “hopeful to advance to a phase 3 confirmatory trial” of the stem cell therapy candidate.

Abivax (ABVX) stock surged on Obefazimod trial success and takeover rumors. Learn if valuation risks now outweigh reward.

APIs (Application Programming Interfaces) have become the digital backbone of modern enterprises, seamlessly linking mobile applications, cloud platforms, and partner ecosystems. As their adoption ...

Novartis' phase III PREVENT trial of Cosentyx in patients with nr-axSpA meets primary endpoint: Basel Wednesday, November 13, 2019, 09:00 Hrs [IST] Novartis, a leader in rheumatol ...

After a weak first half, the drug and biotech sector regained momentum in the latter part of 2025, setting the stage for a ...

The cellular therapy landscape continues to evolve beyond hematologic malignancies, now making significant progress in solid ...

Takeda Canada Inc. (“Takeda”) is pleased to announce positive topline results for the two pivotal Phase 3 randomized, ...